{"pre_text": ["abiomed , inc .", "and subsidiaries notes to consolidated financial statements 2014 ( continued ) note 14 .", "income taxes ( continued ) on april 1 , 2007 , the company adopted financial interpretation fin no .", "48 , accounting for uncertainty in income taxes 2014an interpretation of fasb statement no .", "109 ( 201cfin no .", "48 201d ) , which clarifies the accounting for uncertainty in income taxes recognized in an enterprise 2019s financial statements in accordance with fasb statement no .", "109 , accounting for income taxes .", "fin no .", "48 prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return .", "fin no .", "48 also provides guidance on derecognition , classification , interest and penalties , accounting in interim periods , disclosure , and transition and defines the criteria that must be met for the benefits of a tax position to be recognized .", "as a result of its adoption of fin no .", "48 , the company recorded the cumulative effect of the change in accounting principle of $ 0.3 million as a decrease to opening retained earnings and an increase to other long-term liabilities as of april 1 , 2007 .", "this adjustment related to state nexus for failure to file tax returns in various states for the years ended march 31 , 2003 , 2004 , and 2005 .", "the company initiated a voluntary disclosure plan , which it completed in fiscal year 2009 .", "the company elected to recognize interest and/or penalties related to income tax matters in income tax expense in its consolidated statements of operations .", "as of march 31 , 2009 , the company had remitted all outstanding amounts owed to each of the states in connection with the outstanding taxes owed at march 31 , 2008 .", "as such , the company had no fin no .", "48 liability at march 31 , 2009 .", "on a quarterly basis , the company accrues for the effects of uncertain tax positions and the related potential penalties and interest .", "it is reasonably possible that the amount of the unrecognized tax benefit with respect to certain of the unrecognized tax positions will increase or decrease during the next 12 months ; however , it is not expected that the change will have a significant effect on the company 2019s results of operations or financial position .", "a reconciliation of the beginning and ending balance of unrecognized tax benefits , excluding accrued interest recorded at march 31 , 2009 ( in thousands ) is as follows: ."], "post_text": ["the company and its subsidiaries are subject to u.s .", "federal income tax , as well as income tax of multiple state and foreign jurisdictions .", "the company has accumulated significant losses since its inception in 1981 .", "all tax years remain subject to examination by major tax jurisdictions , including the federal government and the commonwealth of massachusetts .", "however , since the company has net operating loss and tax credit carry forwards which may be utilized in future years to offset taxable income , those years may also be subject to review by relevant taxing authorities if the carry forwards are utilized .", "note 15 .", "commitments and contingencies the company 2019s acquisition of impella provided that abiomed was required to make contingent payments to impella 2019s former shareholders as follows : 2022 upon fda approval of the impella 2.5 device , a payment of $ 5583333 2022 upon fda approval of the impella 5.0 device , a payment of $ 5583333 , and 2022 upon the sale of 1000 units of impella 2019s products worldwide , a payment of $ 5583334 .", "the two milestones related to sales and fda approval of the impella 2.5 device were achieved and paid prior to march 31 , 2009 .", "in april 2009 , the company received fda 510 ( k ) clearance of its impella 5.0 product , triggering an obligation to pay the milestone related to the impella 5.0 device .", "in may 2009 , the company paid $ 1.8 million of this final milestone in cash and elected to pay the remaining amount through the issuance of approximately 664612 shares of common stock. ."], "table": [["balance at march 31 2008", "$ 168"], ["reductions for tax positions for closing of the applicable statute of limitations", "-168 ( 168 )"], ["balance at march 31 2009", "$ 2014"]], "table_ori": [["Balance at March 31, 2008", "$168"], ["Reductions for tax positions for closing of the applicable statute of limitations", "(168)"], ["Balance at March 31, 2009", "$—"]]}

Question: what portion of the last payment for the final milestone was paid through the issuance of common stock?
Evidence:
text_28: commitments and contingencies the company 2019s acquisition of impella provided that abiomed was required to make contingent payments to impella 2019s former shareholders as follows : 2022 upon fda approval of the impella 2.5 device , a payment of $ 5583333 2022 upon fda approval of the impella 5.0 device , a payment of $ 5583333 , and 2022 upon the sale of 1000 units of impella 2019s products worldwide , a payment of $ 5583334 .
text_31: in may 2009 , the company paid $ 1.8 million of this final milestone in cash and elected to pay the remaining amount through the issuance of approximately 664612 shares of common stock. .
Program: divide(5583334, const_1000000), subtract(#0, 1.8), divide(#1, #0)
Answer:
str_answer: 67.7%
exe_answer: 0.67761